March 2000
AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p169
Academic Journal
Reports that the AIDS Research Alliance in Los Angeles, California, is recruiting subjects for a small phase I/II trial of an antiretroviral combination. Investigation of the anti-malaria drug hydroxychloroquine; Antiviral activity exhibited by the drug.


Related Articles

  • Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Mauskopf, J.A.; Cates, S.C.; Griffin, A.D.; Neighbors, D.M.; Lamb, S.C.; Rutherford, C. // PharmacoEconomics;2000, Vol. 17 Issue 6, p611 

    Objective: To use data from a clinical trial of zanamivir, a new antiviral drug, to estimate the costs and effectiveness of alternative treatment strategies for a high-risk population in Australia visiting a physician for treatment of influenza or influenza-like illness within 36...

  • Trimeris/Roche Report Good Test Results From T-20 HIV Drug.  // Biotech Business;Dec99, Vol. 12 Issue 12, p2 

    Reports that Trimeris Inc. and Hoffman-La Roche Inc. have announced 16-week results from an evaluation of T-20 HIV drug in an on-going clinical trial in December 1999.

  • HIVers needed for flu study. Bajko, Matthew S. // Bay Area Reporter;11/12/2009, Vol. 39 Issue 46, p1 

    The article reports on the clinical trial of the triple combination antiviral drug therapy (TCAD) to be made by the Quest Clinical Studies, the Covenant Medical Group, and Adamas Pharmaceuticals and will be participated by the people with human immunodeficiency virus (HIV) who contract influenza.

  • New Hope with CD4. Helquist, Michael // Advocate;10/11/88, Issue 509, p22 

    Discusses the potential of anti-AIDS drug, CD4. Clinical trials of CD4.

  • EASL Roundup.  // BioWorld Today;4/20/2012, Vol. 23 Issue 77, p7 

    The article reports that Phase II study of Abbott's direct-acting antivirals in hepatitis C (HCV) has indicated more than 90 percent of patients new to HCV treatment achieved sustained viral response through 12 weeks (SVR12).

  • The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Parato, Kelley A; Breitbach, Caroline J; Le Boeuf, Fabrice; Wang, Jiahu; Storbeck, Chris; Ilkow, Carolina; Diallo, Jean-Simon; Falls, Theresa; Burns, Joseph; Garcia, Vanessa; Kanji, Femina; Evgin, Laura; Hu, Kang; Paradis, Francois; Knowles, Shane; Hwang, Tae-Ho; Vanderhyden, Barbara C; Auer, Rebecca; Kirn, David H; Bell, John C // Molecular Therapy;Apr2012, Vol. 20 Issue 4, p749 

    Oncolytic viruses are generally designed to be cancer selective on the basis of a single genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and lac-Z transgenes that is designed to...

  • AASLD 2010.  // BioWorld Today;11/2/2010, Vol. 21 Issue 212, p8 

    The article reports that Anadys Pharmaceuticals Inc. presented the clinical trial results of its ANA598 direct-acting antiviral which showed an acceleration of virus levels in patients.

  • New Drugs ddI and ddC Continue to Show Promise. Waites, Larry // Advocate;12/18/90, Issue 566, p61 

    Examines the effectiveness of the anti-AIDS drugs ddI and ddC, as studied in trials in the U.S. in the 1990s. Updates on the expanded-access programs by drug firms Bristol-Myers Squibb and Hoffmann-LaRoche; Effectiveness of ddI and ddC against strains of HIV that have developed resistance to...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Jan2003, Vol. 17 Issue 1, p43 

    Reports on key developments concerning antivirals in the U.S. as of January 2003. Release by the Food and Drug Administration of new guidelines to help sponsors of clinical trials involving antiretroviral agents; Creation by the state of Rhode Island of post-exposure treatment guidelines for...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Apr2003, Vol. 17 Issue 4, p199 

    Reports on several developments in the field of viral diseases and antivirals in the U.S. as of April 1, 2003. Neat trial investigation on antiretroviral infection results announced at the 10th Conference on Retroviruses and Opportunistic Infections held in Boston, Massachusetts; Impact of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics